Reply  by Antman, Elliott M. et al.
Omega-3 Fatty Acids for Secondary Prevention
The American College of Cardiology/American Heart Association
Guidelines for managing ST-elevation myocardial infarction state
clearly and in detail the recommendations for revascularization and
drug therapy along with levels of evidence (1). Unfortunately, the
Executive Summary does not meet this high standard in the
secondary-prevention section, specifically regarding omega-3 fatty
acid or fish oil supplementation. Stating that increased consump-
tion of omega-3 fatty acids should be encouraged falls short of the
recommendations of the AHA last year (2). These recommenda-
tions clearly state that for patients with documented coronary heart
disease (CHD), the AHA recommends 1 g of eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA) (combined per day).
In practice, this means taking one or two fish oil capsules per day
depending on concentration. This dose of EPA and DHA (fish
oil) ought to be regarded not as diet therapy but as a supplement
that can easily be prescribed by cardiologists.
In the GISSI-P trial that involved 11,324 patients, EPA and
DHA supplementation demonstrated that one capsule of fish oil
(850 to 882 mg omega-3) was associated with a 53% reduction of
sudden death in the first four months (3). The benefit was not
related to lipid modification.
It is unfortunate that the practice guidelines committee missed
a golden opportunity to reinforce the recommendations of the
nutrition committee to prescribe 1 g of EPA and DHA (com-
bined) per day for all patients with documented CHD.
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REPLY
In the 2004 ACC/AHA guidelines for the management of patients
with ST-elevation myocardial infarction (STEMI) (1,2) we adapted
the existing AHA/ACC guidelines for preventing heart attack and
death in patients with atherosclerotic cardiovascular disease: 2001
update (3) to develop the recommendations for preventive therapy at
the time of discharge from the hospital after STEMI. Also included
as a reference in the STEMI guidelines are the AHA evidence-based
guidelines for cardiovascular disease prevention in women (4), which
include several references supporting the benefits of omega-3 fatty
acids for patients with coronary heart disease. Each of these state-
ments emphasizes the need for supplementation with omega-3 fatty
acids. Inasmuch as the AHA secondary prevention guidelines are now
undergoing revision with a projected date of publication in early 2005
and because secondary prevention was not the purview of the STEMI
statement, specific recommendations about doses of omega-3 fatty
acids were not made as part of the STEMI guideline. The 2003
publication (5) cited by Dr. Colquhoun is an editorial statement from
the Nutrition Committee of the AHA and not a formal ACC/AHA
guideline. It is expected that omega-3 fatty acids as well as other
important dietary measures will receive continued emphasis in the
upcoming guidelines on secondary prevention for cardiovascular
disease.
Dr. Kessler questions the utility of certain recommendations in the
recently published ACC/AHA STEMI guidelines and then makes
rather broad statements regarding all cardiovascular guidelines (2).
His main point seems to be that self-evident clinical truths are
“nonempiric,” cannot be experimentally proven, and should not be
handled in the recommendation scheme in the same fashion as
empiric or evidence-based recommendations. The Task Force on
Practice Guidelines for the ACC and AHA recognized the need to
account for recommendations that are agreed to represent the best
clinical practice but have not been formally tested in large-scale
clinical trials—this is handled by the level of evidence component of
the recommendation schema. A recommendation that reflects the
consensus of a group of experts (members of the writing committees,
peer reviewers of the document, and administrative review by the
governing bodies of the ACC and AHA) is assigned a Level of
Evidence of C.
To make his point, Dr. Kessler cites two examples in the STEMI
guideline but unfortunately misquotes the recommendations and fails
to represent the spirit and intent of the writing committee accurately.
The recommendation about obtaining an electrocardiogram (ECG)
centers around the 10-min time frame for obtaining the tracing in the
emergency department. Simply obtaining an ECG tracing in a patient
with STEMI is inadequate if it is not obtained promptly so that
myocardium can be salvaged by reperfusion. In fact, the recommen-
dation in question has actually become a performance measure to
track how well health care teams are handling STEMI patients.
The second recommendation questioned by Dr. Kessler relates to
coronary angiography. Again he misquotes the recommendation. The
Class III recommendation states that coronary angiography should
not be performed in patients who are not considered candidates for
revascularization. Dr. Kessler claims this means the risk of revascu-
larization outweighs the benefits. Although that is one aspect of what
the writing committee had in mind in crafting that recommendation,
there were several others. We were concerned that some clinicians
recommend that all patients with STEMI undergo coronary angiog-
raphy before discharge. Such a practice is not cost-effective if there is
no intention to perform revascularization because of a perceived
unfavorable risk:benefit ratio, an absolute refusal to consider revascu-
larization by the patient, or a limited life expectancy of the patient
such that the likelihood of achieving a benefit from revascularization
is extremely small. Inappropriate referral for coronary angiography not
only increases the cost to the health care system but exposes the
patient to risks of the procedure without any potential gain from the
information provided.
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